Compare DexCom, Inc. (DXCM) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Williams-Sonoma, Inc. — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Williams-Sonoma, Inc. trades at $241.78 (market cap $28.15B). The key difference: DexCom, Inc. and Williams-Sonoma, Inc. are close in size by market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Williams-Sonoma, Inc. for 59 Days on average.
| DXCM | WSM | |
|---|---|---|
Market Cap | $31.86B | $28.15B |
Volume | 3,607,070 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $251.81 |
52-Week Low | $54.84 | $168.64 |
Typical Hold Time | 62 Days | 59 Days |
Enterprise Value | $31.32B | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Williams-Sonoma (WSM) trades at $239.00, down 0.61% on the day, near its pivot point of $239 with bullish moving average signals. The company demonstrates strong profitability with a 14.73% net income margin and 54.96% ROE, supported by three consecutive quarterly earnings beats. Recent news highlights market share gains and margin expansion through reduced discounting, with a new Pottery Barn collaboration and store openings fueling growth.
The outlook remains positive with a consensus price target of $246.31 offering 3% upside, though risks include housing market sensitivity and high valuation multiples. Earnings growth and disciplined cost control position WSM for continued outperformance, but investors should monitor competitive pressures and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
